T. James Hippel's most recent trade in Bio-Techne Corp was a trade of 34,634 Restricted Stock Units done . Disclosure was reported to the exchange on Nov. 1, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2024 | 34,634 | 34,634 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 13,159 | 13,159 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 13,159 | 113,085 (0%) | 0% | 0 | Common Stock | |
| Bio-Techne | James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.31 per share. | 01 Nov 2024 | 6,475 | 106,610 (0%) | 0% | 75.3 | 487,632 | Common Stock |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 32,417 | 32,417 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 24,062 | 24,062 | - | - | Performance Restricted Stock Units | |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 12,031 | 12,031 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 53,000 | 53,867 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.26 per share. | 02 Aug 2024 | 53,000 | 136,002 (0%) | 0% | 31.3 | 1,656,780 | Common Stock |
| Bio-Techne | James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.35 per share. | 02 Aug 2024 | 36,076 | 99,926 (0%) | 0% | 82.4 | 2,970,859 | Common Stock |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.26 per share. | 23 Jul 2024 | 35,000 | 107,284 (0%) | 0% | 31.3 | 1,094,100 | Common Stock |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jul 2024 | 35,000 | 106,867 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.77 per share. | 23 Jul 2024 | 24,282 | 83,002 (0%) | 0% | 77.8 | 1,888,411 | Common Stock |
| Bio-Techne | T. James Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.26 per share. | 19 Dec 2023 | 47,289 | 104,850 (0%) | 0% | 31.3 | 1,478,254 | Common Stock |
| Bio-Techne | T. Hippel James | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2023 | 47,289 | 141,867 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | Hippel T. James | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.42 per share. | 19 Dec 2023 | 32,966 | 71,884 (0%) | 0% | 77.4 | 2,552,228 | Common Stock |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 45,923 | 45,923 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | T. Hippel James | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 37,314 | 37,314 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 34,442 | 34,442 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | Hippel James T. | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 13,865 | 13,865 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 12,798 | 12,798 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 12,876 | 63,896 (0%) | 0% | 0 | Common Stock | |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 12,876 | 0 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.17 per share. | 05 Aug 2023 | 6,335 | 57,561 (0%) | 0% | 82.2 | 520,547 | Common Stock |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 11,305 | 11,305 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 8,479 | 8,479 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 2,728 | 2,728 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2022 | 3,938 | 0 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2022 | 3,938 | 14,693 (0%) | 0% | 0 | Common Stock | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 382.97 per share. | 07 Aug 2022 | 1,938 | 12,755 (0%) | 0% | 383.0 | 742,196 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 8,822 | 47,589 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 01 Nov 2021 | 8,822 | 19,577 (0%) | 0% | 125.0 | 1,103,191 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 525.61 per share. | 01 Nov 2021 | 3,566 | 16,011 (0%) | 0% | 525.6 | 1,874,318 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 526.50 per share. | 01 Nov 2021 | 2,880 | 13,131 (0%) | 0% | 526.5 | 1,516,321 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 527.50 per share. | 01 Nov 2021 | 1,433 | 11,698 (0%) | 0% | 527.5 | 755,903 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 528.55 per share. | 01 Nov 2021 | 943 | 10,755 (0%) | 0% | 528.6 | 498,427 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 200 | 47,389 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 525.10 per share. | 01 Nov 2021 | 200 | 10,755 (0%) | 0% | 525.1 | 105,020 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 01 Nov 2021 | 200 | 10,955 (0%) | 0% | 125.1 | 25,010 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2021 | 662 | 56,411 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 525.23 per share. | 28 Oct 2021 | 662 | 10,755 (0%) | 0% | 525.2 | 347,704 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 28 Oct 2021 | 662 | 11,417 (0%) | 0% | 125.0 | 82,783 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 525.18 per share. | 28 Oct 2021 | 100 | 10,755 (0%) | 0% | 525.2 | 52,518 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2021 | 10,000 | 0 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 02 Sep 2021 | 10,000 | 20,855 (0%) | 0% | 106.6 | 1,065,900 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 507.22 per share. | 02 Sep 2021 | 9,993 | 10,862 (0%) | 0% | 507.2 | 5,068,600 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 509.14 per share. | 02 Sep 2021 | 7 | 10,855 (0%) | 0% | 509.1 | 3,564 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 10,134 | 10,134 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 06 Aug 2021 | 10,000 | 20,855 (0%) | 0% | 106.6 | 1,065,900 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 10,000 | 10,000 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 7,600 | 7,600 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 477.69 per share. | 06 Aug 2021 | 5,200 | 15,655 (0%) | 0% | 477.7 | 2,484,002 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 3,383 | 12,520 (0%) | 0% | 0 | Common Stock | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 3,383 | 0 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 1,945 | 1,945 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 478.58 per share. | 06 Aug 2021 | 1,800 | 13,855 (0%) | 0% | 478.6 | 861,444 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 481.82 per share. | 06 Aug 2021 | 1,665 | 10,855 (0%) | 0% | 481.8 | 802,230 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 479.96 per share. | 06 Aug 2021 | 1,300 | 12,555 (0%) | 0% | 480.0 | 623,954 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 480.66 per share. | 06 Aug 2021 | 700 | 11,755 (0%) | 0% | 480.7 | 336,462 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 481.61 per share. | 06 Aug 2021 | 300 | 11,455 (0%) | 0% | 481.6 | 144,482 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 483.62 per share. | 06 Aug 2021 | 300 | 11,155 (0%) | 0% | 483.6 | 145,085 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 484.98 per share. | 06 Aug 2021 | 300 | 10,855 (0%) | 0% | 485.0 | 145,494 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 480.70 per share. | 06 Aug 2021 | 100 | 12,455 (0%) | 0% | 480.7 | 48,070 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2021 | 10,000 | 20,000 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 12 Jul 2021 | 10,000 | 19,137 (0%) | 0% | 106.6 | 1,065,900 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 458.81 per share. | 12 Jul 2021 | 1,863 | 11,037 (0%) | 0% | 458.8 | 854,770 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 455.57 per share. | 12 Jul 2021 | 1,773 | 14,563 (0%) | 0% | 455.6 | 807,717 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 457.79 per share. | 12 Jul 2021 | 1,136 | 12,900 (0%) | 0% | 457.8 | 520,055 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 459.64 per share. | 12 Jul 2021 | 800 | 10,237 (0%) | 0% | 459.6 | 367,712 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 453.21 per share. | 12 Jul 2021 | 788 | 16,998 (0%) | 0% | 453.2 | 357,126 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 451.95 per share. | 12 Jul 2021 | 751 | 17,786 (0%) | 0% | 452.0 | 339,416 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 454.15 per share. | 12 Jul 2021 | 662 | 16,336 (0%) | 0% | 454.1 | 300,647 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 460.71 per share. | 12 Jul 2021 | 600 | 9,637 (0%) | 0% | 460.7 | 276,428 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 451.07 per share. | 12 Jul 2021 | 600 | 18,537 (0%) | 0% | 451.1 | 270,640 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 456.41 per share. | 12 Jul 2021 | 527 | 14,036 (0%) | 0% | 456.4 | 240,527 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 462.08 per share. | 12 Jul 2021 | 300 | 9,337 (0%) | 0% | 462.1 | 138,625 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 466.44 per share. | 12 Jul 2021 | 100 | 9,137 (0%) | 0% | 466.4 | 46,644 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 463.56 per share. | 12 Jul 2021 | 100 | 9,237 (0%) | 0% | 463.6 | 46,356 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2021 | 9,942 | 30,000 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 07 Jun 2021 | 9,942 | 19,079 (0%) | 0% | 106.6 | 1,059,718 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 421.93 per share. | 07 Jun 2021 | 2,396 | 13,147 (0%) | 0% | 421.9 | 1,010,935 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 420.66 per share. | 07 Jun 2021 | 2,029 | 15,543 (0%) | 0% | 420.7 | 853,523 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 422.81 per share. | 07 Jun 2021 | 2,000 | 11,147 (0%) | 0% | 422.8 | 845,628 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 423.74 per share. | 07 Jun 2021 | 1,700 | 9,447 (0%) | 0% | 423.7 | 720,357 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 419.88 per share. | 07 Jun 2021 | 1,507 | 17,572 (0%) | 0% | 419.9 | 632,765 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 424.59 per share. | 07 Jun 2021 | 310 | 9,137 (0%) | 0% | 424.6 | 131,623 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 12 Feb 2021 | 10,000 | 19,137 (0%) | 0% | 106.6 | 1,065,900 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 10,000 | 39,942 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 400.32 per share. | 12 Feb 2021 | 9,400 | 9,737 (0%) | 0% | 400.3 | 3,762,998 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 401.52 per share. | 12 Feb 2021 | 600 | 9,137 (0%) | 0% | 401.5 | 240,911 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2021 | 10,000 | 49,942 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 11 Jan 2021 | 10,000 | 19,137 (0%) | 0% | 106.6 | 1,065,900 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 334.39 per share. | 11 Jan 2021 | 3,990 | 11,146 (0%) | 0% | 334.4 | 1,334,219 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 333.23 per share. | 11 Jan 2021 | 2,501 | 15,136 (0%) | 0% | 333.2 | 833,415 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 334.98 per share. | 11 Jan 2021 | 2,009 | 9,137 (0%) | 0% | 335.0 | 672,983 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 331.61 per share. | 11 Jan 2021 | 700 | 17,637 (0%) | 0% | 331.6 | 232,127 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 330.26 per share. | 11 Jan 2021 | 400 | 18,337 (0%) | 0% | 330.3 | 132,106 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 328.68 per share. | 11 Jan 2021 | 400 | 18,737 (0%) | 0% | 328.7 | 131,472 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2020 | 7,391 | 59,942 | - | - | Stock Option (Right to Buy) | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2020 | 8,809 | 0 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2020 | 4,438 | 0 | - | - | Restricted Stock Units |